Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Fifth Third Bancorp Common Stock (FITB) vs Indivior Pharmaceuticals Inc. Common Stock (INDV) Price & Performance

Fifth Third Bancorp Common StockTrade
Indivior Pharmaceuticals Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Fifth Third Bancorp Common Stock vs Indivior Pharmaceuticals Inc. Common Stock — how do they compare? Fifth Third Bancorp Common Stock trades at $50.34 (market cap $45.02B), while Indivior Pharmaceuticals Inc. Common Stock trades at $34.71 (market cap $4.03B). The key difference: Fifth Third Bancorp Common Stock is far larger — about 11.2× Indivior Pharmaceuticals Inc. Common Stock's market cap, and Fifth Third Bancorp Common Stock pays a 3.38% dividend while Indivior Pharmaceuticals Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fifth Third Bancorp Common Stock for 6 Days and Indivior Pharmaceuticals Inc. Common Stock for 0 Days on average.

FITBINDV
Market Cap
$45.02B$4.03B
Volume
6,867,3882,781,171
Sector
FinancialsHealth
52-Week High
$59.37$41.83
52-Week Low
$40.36$24.09
Typical Hold Time
6 Days0 Days
Enterprise Value
$62.91B$4.32B
Dividend Yield
3.38%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Fifth Third Bancorp Common Stock

Fifth Third Bancorp (FITB) trades at $50.22, down 1.18% with bearish technical signals from moving averages. The stock shows solid fundamentals with a 22.36% net income margin and has beaten earnings expectations in two of the last three quarters. Recent news highlights the bank's innovation banking launch and Q3 guidance tracking at the high end of ranges post-Comerica conversion. Analyst consensus remains strongly positive with a $62.63 price target representing 25% upside potential.

FITB presents a compelling value opportunity with reasonable valuation multiples (P/E 16.91, P/B 1.41) and strong profitability metrics. Key risks include regulatory scrutiny of banking practices and integration challenges from the Comerica acquisition. The upcoming Q3 earnings report on October 19 will be crucial for validating the bank's growth trajectory and capital management strategy.

Indivior Pharmaceuticals Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FITB

No sentiment data available yet.

INDV
100% Buy0% Sell
Avg holding period · 0 Days

About Fifth Third Bancorp Common Stock

Fifth Third Bancorp provides retail and commercial banking, lending, payments, and wealth management services in the United States.

Read more on FITB →

About Indivior Pharmaceuticals Inc. Common Stock

Indivior Pharmaceuticals, Inc. is a pharmaceutical company focused on treatments for opioid use disorder and other addiction-related conditions, including its Suboxone film and tablet products.

Read more on INDV →